InicioJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
124,39 $
Después del cierre:(0,00 %)0,00
124,39 $
Cerrados: 27 ene, 16:01:48 GMT-5 · USD · NASDAQ · Renuncia de responsabilidad
Cierre anterior
122,04 $
Intervalo diario
122,12 $ - 124,83 $
Intervalo anual
99,06 $ - 134,17 $
Cap. bursátil
7519,95 M USD
Volumen medio
570,65 mil
Relación precio-beneficio
17,52
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos | 1054,97 M | 8,52 % |
Gastos operativos | 683,15 M | -2,07 % |
Ingresos netos | 215,06 M | 46,48 % |
Margen de beneficio neto | 20,38 | 34,97 % |
Beneficios por acción | 6,61 | 36,57 % |
EBITDA | 425,44 M | 27,02 % |
Tipo impositivo efectivo | -7,25 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 2618,15 M | 64,40 % |
Activos totales | 12,26 mil M | 9,39 % |
Responsabilidades totales | 8084,65 M | 4,80 % |
Patrimonio total | 4171,07 M | — |
Acciones en circulación | 60,45 M | — |
Precio-valor contable | 1,77 | — |
Rentabilidad económica | 5,51 % | — |
Retorno sobre capital | 6,53 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | 215,06 M | 46,48 % |
Efectivo de operaciones | 398,75 M | 29,80 % |
Efectivo de inversión | 214,09 M | 222,83 % |
Efectivo de financiación | 246,43 M | 413,95 % |
Variación neta del flujo de caja | 862,33 M | 1.515,28 % |
Flujo de caja libre | 299,28 M | -4,88 % |
Información sobre la empresa
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Director ejecutivo
Fundación
2003
Sitio web
Empleados
2.800
